HomeCompareJDNRX vs JNJ

JDNRX vs JNJ: Dividend Comparison 2026

JDNRX yields 15.38% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JDNRX wins by $34.7K in total portfolio value
10 years
JDNRX
JDNRX
● Live price
15.38%
Share price
$67.72
Annual div
$10.41
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.8K
Annual income
$3,969.49
Full JDNRX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — JDNRX vs JNJ

📍 JDNRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJDNRXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JDNRX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JDNRX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JDNRX
Annual income on $10K today (after 15% tax)
$1,306.91/yr
After 10yr DRIP, annual income (after tax)
$3,374.07/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JDNRX beats the other by $2,670.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JDNRX + JNJ for your $10,000?

JDNRX: 50%JNJ: 50%
100% JNJ50/50100% JDNRX
Portfolio after 10yr
$37.4K
Annual income
$2,398.63/yr
Blended yield
6.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

JDNRX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JDNRX buys
0
JNJ buys
0
No recent congressional trades found for JDNRX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJDNRXJNJ
Forward yield15.38%3.36%
Annual dividend / share$10.41$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$54.8K$20.0K
Annual income after 10y$3,969.49$827.78
Total dividends collected$26.9K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JDNRX vs JNJ ($10,000, DRIP)

YearJDNRX PortfolioJDNRX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,238$1,537.54$10,676$355.77+$1.6KJDNRX
2$14,853$1,758.48$11,407$389.39+$3.4KJDNRX
3$17,887$1,994.64$12,198$426.53+$5.7KJDNRX
4$21,384$2,244.98$13,056$467.62+$8.3KJDNRX
5$25,389$2,508.32$13,987$513.12+$11.4KJDNRX
6$29,950$2,783.29$14,998$563.56+$15.0KJDNRX
7$35,115$3,068.45$16,098$619.52+$19.0KJDNRX
8$40,935$3,362.25$17,295$681.69+$23.6KJDNRX
9$47,464$3,663.13$18,599$750.82+$28.9KJDNRX
10$54,756$3,969.49$20,022$827.78+$34.7KJDNRX

JDNRX vs JNJ: Complete Analysis 2026

JDNRXStock

The fund pursues its investment objective by normally investing in dividend-paying common stocks with strong growth potential. It may also invest in foreign securities. The portfolio manager applies a “bottom up” approach in choosing investments. In other words, the portfolio manager looks at companies one at a time to determine if a company is an attractive investment opportunity and if it is consistent with the fund’s investment policies.

Full JDNRX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this JDNRX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JDNRX vs SCHDJDNRX vs JEPIJDNRX vs OJDNRX vs KOJDNRX vs MAINJDNRX vs ABBVJDNRX vs MRKJDNRX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.